Lonza signs exclusive agreement with Index Ventures
Five year agreement includes all companies where Index Ventures will be the majority shareholder
Lonza and Index Ventures, LLP announced an exclusive agreement for process development and cGMP production for all biological products in the portfolio of companies where Index is the major investor.
Over the course of the agreement, additional development and manufacturing projects will be added to the product list, as future investments are made by Index.
“This agreement shows that Lonza’s value to a company’s product development pipeline is being recognized more widely by investors in biotech companies,” said Dr. Stephan Kutzer, COO Lonza Pharma&Biotech. “This multi-product agreement demonstrates Lonza’s ability to offer world-class expression platforms in combination with secure manufacturing capabilities for the complete product lifecycle.”
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.